SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

July 28, 2015 07:00 ET

Dr. Camilo Vieira and Pessoa Parents Join CTD Holdings Family and Physicians Listening Circle on NPC Treatment

Listening Circle International Membership Now Represents the U.S., Europe and Brazil

ALACHUA, FL--(Marketwired - July 28, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology growth company that develops cyclodextrin-based products for the treatment of disease, today announced Dr. Camilo Vieira, MD, and Roberto and Renata Pessoa of Salvador, Brazil, would become members of the company's Family and Physicians Listening Circle. This group serves as an information-sharing forum for families, physicians and CTD's International Clinical Program team as they work together to develop the orphan drug designated Trappsol® Cyclo™ product for the treatment of Niemann-Pick Type C (NPC), a rare and serious disease found primarily in children.

Dr. Vieira is a pediatric neurologist at Clinica Citta, Salvador, Brazil. He has successfully used CTD's Trappsol® Cyclo™ to treat NPC patients since 2010 under the Brazilian Health Surveillance Agency (ANVISA) compassionate use program.

Roberto and Renata Pessoa are parents of two children with NPC who are under the care of Dr. Vieira. The Pessoas gained access to Trappsol® Cyclo™ for their children by working with legal authorities in the Brazilian state of Bahia. The Pessoa's work encouraged other NPC families to engage with legal authorities in their own states to gain access to Trappsol Cyclo.

"I am pleased to join this group of committed parents and physicians to strengthen our collective efforts in the fight against NPC," said Dr. Vieira. "It is an honor to work with this group."

"We continue growing the CTD Family and Physicians Listening Circle, and I am delighted to welcome these new members from Brazil," said Dr. Sharon Hrynkow, a member of CTD's Scientific Advisory Board who played a key role in bringing the Listening Circle into existence. "Their insights, having used Trappsol® Cyclo™ for five years, will be invaluable to other families and to the company's International Clinical Program team."

Dr. Vieira and the Pessoas join Listening Circle Co-Chairs Sue French of the UK, and Dr. Caroline Hastings of the US, and Listening Circle members David French, Dr. Robin Lachmann, both of the UK, and Dr. Begoña Arias of Madrid.

"The international expansion of the Family and Physicians Listening Circle enhances our leadership in establishing Trappsol® Cyclo™ as the preeminent treatment in the fight against NPC," said Scott Fine, CTD Executive Chairman. "The insights and knowledge of the Pessoas, Dr. Viera and other members of our Listening Circle will help guide CTD's clinical development program and assist families tackling NPC globally."

About the Company:

CTD Holdings, Inc. is a biotechnology growth company developing cyclodextrin-based products for the treatment of disease. Its Sphingo Biotechnology, Inc. division is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann-Pick Type C, a rare and fatal genetic disease in young children. Additional indications for the active ingredient in Trappsol® Cyclo™, including peripheral artery disease, diabetic nephropathy, and acute viral infections, are also in development.

The company's other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics and nutrition markets. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com

Safe Harbor Statement:

This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the Company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information